US2016194615A1PendingUtilityA1

Novel 7beta-Hydroxysteroid Dehydrogenases and Their Use

49
Assignee: PHARMAZELL GMBHPriority: Nov 30, 2009Filed: Mar 23, 2016Published: Jul 7, 2016
Est. expiryNov 30, 2029(~3.4 yrs left)· nominal 20-yr term from priority
C12Y 101/01201C12P 33/06C12N 9/0006C12P 33/02C12P 33/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to novel 7β-hydroxysteroid dehydrogenases which are obtainable from bacteria of the genus Collinsella , especially of the strain Collinsella aerofaciens , to the sequences encoding said enzymes, to methods for producing said enzymes and to their use in the enzymatic conversion of cholic acid compounds, and especially in the production of ursodeoxycholic acid (UDCS). The invention also relates to novel methods for the synthesis UDCS.

Claims

exact text as granted — not AI-modified
1 . An isolated recombinant 7β-hydroxysteroid dehydrogenase (7β-HSDH) comprising an amino acid sequence according to SEQ ID NO: 2 or a sequence having at least 90% sequence identity to SEQ ID NO: 2 and having a molecular weight, determined by gel filtration, in the range of 53 to 60 kDa, wherein the recombinant 7β-HSDH is at least capable of catalyzing stereospecific reduction of a 7-ketosteroid to the corresponding 7β-hydroxysteroid. 
     
     
         2 . The recombinant 7β-HSDH as claimed in  claim 1  that is also capable of catalyzing regiospecific hydrogenation of a ketosteroid in the 7-position to the corresponding 7β hydroxysteroid. 
     
     
         3 . A method for the enzymatic synthesis of 7β-hydroxysteroids, wherein the 7-ketosteroid is reduced in the presence of a recombinant 7β-HSDH as claimed in  claim 1 , thereby forming at least one reduction product. 
     
     
         4 . The method as claimed in  claim 3 , wherein the ketosteroid to be reduced is selected from the group consisting of dehydrocholic acid (DHCA), 7-keto-lithocholic acid (7-keto-LCA), 7,12-diketo-lithocholic acid (7,12-diketo-LCA), salts, amides and alkyl esters there. 
     
     
         5 . The method as claimed in  claim 3 , wherein the reduction takes place in the presence of NAD(P)H. 
     
     
         6 . A method for the enzymatic oxidation of 7β-hydroxysteroids, wherein the 7β-hydroxysteroid is oxidized in the presence of a 7β-hydroxysteroid dehydrogenase as claimed in  claim 1 , thereby forming an oxidation product. 
     
     
         7 . The method as claimed in  claim 6 , wherein the 7β-hydroxysteroid is 3,12-diketo-7β-CA or a derivative thereof or a salt, amide or alkyl ester thereof. 
     
     
         8 . The method as claimed in  claim 6 , wherein the oxidation takes place in the presence (and with consumption) of NAD(P)+. 
     
     
         9 . The method as claimed in  claim 5 , wherein the redox equivalents consumed are electrochemically or enzymatically regenerated. 
     
     
         10 . The method as claimed in  claim 10 , wherein consumed NAD(P)H is regenerated by coupling with an NAD(P)H-regenerating enzyme selected from an NAD(P)H dehydrogenase and in particular an alcohol dehydrogenase (ADH). 
     
     
         11 . The method as claimed in  claim 10 , wherein the NAD(P)H-regenerating enzyme is selected from the group consisting of natural, recombinant, isolated and enriched alcohol dehydrogenases (EC 1.1.1.2) and functional equivalents derived therefrom. 
     
     
         12 . A method for the production of ursodesoxycholic acid (UDCA) of the formula (1) 
       
         
           
           
               
               
           
         
       
       wherein 
       R stands for alkyl, NR 1 R 2 , H, an alkali metal ion or N(R3)4+, wherein the residues R 3  are the same or different and stand for H or alkyl, 
       wherein 
       a) a cholic acid (CA) of the formula (2) 
       
         
           
           
               
               
           
         
       
       wherein R has the aforesaid meanings, is optionally chemically oxidized to the dehydrocholic acid (DHCA) of the formula (3) 
       
         
           
           
               
               
           
         
       
       wherein R has the aforesaid meanings; 
       b) DHCA is reduced in the presence of a recombinant 7β-HSDH as claimed  claim 1  to the 3,12-diketo-7β-cholanic acid (3,12-Diketo-7β-CA) of the formula (4) 
       
         
           
           
               
               
           
         
       
       c) 3,12-diketo-7β-CS is reduced in the presence of at least one 3α-hydroxysteroid dehydrogenase (3α-HSDH) to the corresponding 12-keto-ursodesoxycholic add (12-keto UDCA) of the formula (5) 
       
         
           
           
               
               
           
         
       
       wherein R has the aforesaid meanings, and then 
       d) 12-keto-UDCA of the formula (5) is chemically reduced to UDCA; and 
       e) the reaction product is optionally further purified. 
     
     
         13 . The method as claimed in  claim 13 , wherein the steps b) and/or c) are coupled with an (in particular enzymatic) cofactor regeneration step. 
     
     
         14 . The method as claimed in  claim 12 , wherein step b) is coupled with a cofactor regeneration step, in which NADPH is regenerated by alcohol dehydrogenase (ADH) with consumption of a sacrificial alcohol. 
     
     
         15 . 5 The method as claimed in  claim 12 , wherein step c) is coupled with a cofactor regeneration step, in which NADH is regenerated by formate dehydrogenase (FDH) with consumption of formate, or in which NADPH is regenerated by alcohol dehydrogenase (ADH). 
     
     
         16 . The recombinant 7β-HSDH as claimed in  claim 1 , wherein the amino acid sequence has at least 95% sequence identity to SEQ ID NO: 2. 
     
     
         17 . The recombinant 7β-HSDH as claimed in  claim 1 , further comprising a His-Tag fused to a terminus of the amino acid sequence. 
     
     
         18 . An isolated recombinant 7β-hydroxysteroid dehydrogenase (7β-HSDH) comprising an amino acid sequence according to SEQ ID NO: 2 or a sequence having at least 90% sequence identity to SEQ ID NO: 2 and having a molecular weight, determined by gel filtration, in the range of 53 to 60 kDa, wherein the recombinant 7β-HSDH is at least capable of catalyzing stereospecific reduction of a 7-ketosteroid to the corresponding 7β-hydroxysteroid, and wherein the recombinant 7β-HSDH is prepared by a process comprising the steps of:
 cloning a gene comprising the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence having at least 90% sequence homology with SEQ ID NO:1; 
 expressing the cloned gene in a bacterial host; and 
 isolating the expressed protein. 
 
     
     
         19 . The recombinant 7β-HSDH as claimed in  claim 18 , wherein the gene further includes a nucleic acid sequence encoding a His-Tag 
     
     
         20 . The recombinant 7β-HSDH as claimed in  claim 18 , comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2. 
     
     
         21 . The recombinant 7β-HSDH as claimed in  claim 18 , wherein the gene is cloned in vector pET28a+. 
     
     
         22 . The recombinant 7β-HSDH as claimed in  claim 18 , wherein the bacterial host is  E. coli  BL21(DE3).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.